News & Publications


Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.

Prous Institute to Present in Silico Approaches to Neuroplasticity Modulation at 8th Fens Forum of Neuroscience

Innovative in silico approach opens new avenues in drug discovery for the treatment of CNS disorders


Barcelona: Prous Institute for Biomedical Research is presenting the results of its work to construct a predictive computational system mimicking the different processes involved in neuroplasticity with the aim of identifying molecules with potential pharmacological activity.  

Neuroplasticity is widely considered to be a cellular mechanism underlying learning and memory and covers broad disease areas where the scientific challenge to alleviate human suffering is enormous. Studies to understand the molecular mechanisms of learning, memory and synaptic plasticity aim to achieve different treatment approaches for a variety of disorders.  A series of compounds identified at Prous Institute exhibit cognitive effects in behavioral learning tests after acute administration and last several days after a single dose.  This is an important finding as existing compounds only show their effects on memory improvement after chronic administration.  

Full results will be presented as part of the poster session on Tuesday, July 17th, from 13:30 to 15:30  (J. Prous et al. 8th FENS Forum (Federation of European Neuroscience Societies)  Barcelona, July 14-18, 2012), Abstract 2503).  


About Prous Institute for Biomedical Research  

Prous Institute for Biomedical Research (PIBR) is a privately-held biotechnology company focused on the discovery of novel therapeutics through the application of its proprietary drug discovery platform, Symmetry®, and expertise in synthetic chemistry, molecular and cellular biology, and pharmacology. Our uniqueness and our core competencies reflect 50 years of experience creating and managing biomedical knowledge.